Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.

Anti-cancer drugs - 1 Jul 2011

Boehrer Simone, Schroeder Petra, Mueller Tina, Atz Judith, Chow Kai Uwe

Abstract excerpt

Monoclonal antibodies such as rituximab and alemtuzumab show considerable therapeutic efficacy in chronic lymphocytic leukaemia (CLL). Aiming to further improve antineoplastic efficacy, the trifunctional bispecific antibody FBTA05 was developed. FBTA05 is thought to function by simultaneously binding B cells and T cells by its variable regions and by recruiting FcγR-positive accessory immune cells by its intact...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antibodies, Neoplasm

Share to Antigens, CD20

Share to Cytotoxicity Tests, Immunologic

Share to Granzymes

Share to Perforin

Share to Rituximab

Source

Identifiers

PMID: 21637160
DOI: 10.1097/CAD.0b013e328344887f

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.PMID 21637160Read ↗

A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy.Semantic proximity Read ↗

Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphomaSemantic proximity Read ↗

Anti-CD19/CD20 bispecific antibody with dual Fc domains mediates enhanced effector functions and durable depletion of memory B cells in vivoSemantic proximity Read ↗

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesSemantic proximity Read ↗

Therapeutic targeting of chronic lymphocytic leukemia by silver nanoparticlesSemantic proximity Read ↗

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.Semantic proximity Read ↗

Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.Semantic proximity Read ↗

CD20‐Specific Immunoligands Engaging NKG2D Enhance γδ T Cell‐Mediated Lysis of Lymphoma CellsSemantic proximity Read ↗

Bispecific CD20xCD40 Antibodies Achieve Multi-Lineage Modulation of Humoral and Cellular ImmunitySemantic proximity Read ↗

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.Semantic proximity Read ↗

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer PatientsSemantic proximity Read ↗

Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular CytotoxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.